摘要
此文报告了2004年2月-2006年8月经临床确诊为呼吸道感染的患者共1827例,其中卡他莫拉氏菌235株,占12.8%。在235例卡他莫拉氏菌感染中,145例为COPD。对235株卡他莫拉氏菌进行药敏试验。结果表明其对青霉素、氨苄青霉素的耐药率达80%以上;对环丙沙星的耐药率达20.4%;对头孢曲松、头孢噻肟、优普同(头孢呱酮-舒巴坦钠)的耐药率分别为3.8%、5.1%及1.3%;对庆大霉素、丁胺卡钠的耐药率均为8.5%;235株卡他莫拉氏菌产β-内酰胺酶率为89.76%,应选用对β-内酰胺酶稳定的头胞菌素、氨基甙及喹诺酮类抗菌药物。
We have retrospectively studied 1,827 cases with respiratory infections administered from February, 2004 to August, 2006, and 235 strains of Moraxella catarrhalis （ 12.8 % ） were isolated. Among the 235 cases of Moraxella catarrhalis respiratory infections 145 patients were combined with chronic obstructive pulmonary disease （COPD）. The antimicrobial susceptibility of these 235 clinical strains was tested. The rates of resistance to penicillin and ampicillin were both more than 80 % ; to ceftriaxone, cefotaxime, and cefoperazone-sulbactam were 3.8 %, 5.1% and 1.3 % ; and to gentamicin and amikacin wereall 8.5 %. The rate of these 235 strains of Moraxella catarrhalis produce β- lactamase was 89.76%. These results suggest that the antibiotic choice should be the drugs that are stable to β- lactamase, such as cephalosporins, aminoglycosides and quindones.
出处
《实用预防医学》
CAS
2007年第4期1235-1237,共3页
Practical Preventive Medicine
关键词
卡他莫拉氏菌
呼吸道感染
药敏试验
Moraxella catarrhails
Respiratory infection
Drug sensitive test
